Philip S. Low

Next Generation Targeted Therapeutics



AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies

IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies



Cancer Drug Discovered in Indiana to Power Indy Novartis Plant

Novartis in Indy

This Is Purdue - Full Interview with Professor Philip Low

Inside Indiana Business - Malaria

Cancer Network Interview

“FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer” Mar 4, 2023 ONCOLOGY Staff Oncology ONCOLOGY Vol 37, Issue 2 Volume 37 Issue 2 Pages: 53-54 (with my picture on the journal cover) Royalty income for Pluvicto

Video interview at AACR 2023


Wlfi News: Purdue cancer research lab receives $8.5 million estate gift

Inside Indiana Business: Renowned Purdue Researcher Earns Another FDA Approval

U.S. Food & Drug Administration: FDA approves Pluvicto for metastatic castration-resistant prostate cancer

Purdue News: Award honors chemist for fight to beat cancer, save lives

Medical World News: Inside the Practice: Phillip Low, PhD, on the Development and Approval of Pafolacianine



Purdue Research Foundation: Phil Low's seven startups and their latest news

Inside Indiana Business: FDA Approves ‘Illuminating’ Drug for Spotting Cancer

U.S. Food & Drug Administration: FDA Approves Ctyalux(pafolacianine), a New Imaging Drug to Help Identify Ovarian Cancer Lesions

Novartis: FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)

Purdue News: FDA approves pioneering drug for ovarian cancer surgery

Purdue Center for Cancer Research: Member Feature

Globenewswire: Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

CISION PR Newswire: On Target Laboratories Announces U.S. FDA Acceptance and Priority Review of New Drug Application for pafolacianine sodium injection for Identification of Ovarian Cancer During Surgery



New Cancer Immunotherapy

Inside Indiana Business

Endpoints – MPM backs $53M round for a bold concept: Let patients make their own CAR-T in vivo:

Pulmonary Fibrosis News -

Purdue News: Venture capitalists, Purdue innovations, startups establish winning combination for moving life-changing technologies to public



Successful Purdue entrepreneurs provide targeted advice to faculty and staff entrepreneurs entering startup world

Purdue startup Endocyte sold in $2.1B deal with pharmaceutical giant Novartis

$2.1B Endocyte Deal a Record-Breaker

Great Minds Talk Cancer

$1.7 million SBIR grant fast-tracks faster bone fracture healing

Indiana life sciences firms raise record $111M in venture capital in 2017

Prof. Philip S. Low gives a talk on targeted therapy at IISc


Purdue-based biotech company aims to treat cancer by making cancer cells appear to glow

Desi scientist in US discovers molecule that illuminates cancer cells


Purdue research may expand engineered T-cell cancer treatment

Purdue Centre for Drug Discovery Targeting Tumors with Engineered T-Cell Therapy

Research could expand engineered T-cell cancer treatment


Not-for-profit startup aims to evaluate Purdue drug compounds before clinical trials

Dr. Philip Low Honored With 2015 AACR Award for Outstanding Achievement in Chemistry in Cancer Research


On Target Laboratories begins Phase 2 clinical trials for its cancer imaging agent

New technology could 'light up' cancer cells and improve surgical outcomes

Purdue University discovery leads to Endocyte drug


Endocyte founder Philip S. Low awarded BioCrossroads 2013 Watanabe Life Sciences Champion of the Year


Glow-In-the-Dark Cells Help Find Ovarian Cancer